A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Namodenoson (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Can-Fite BioPharma
- 11 Jan 2018 According to Can-Fite BioPharma media release, the company anticipates completing enrolment for this study in the next twelve months.
- 27 Nov 2017 According to a Can-Fite BioPharma media release, first patient has been enrolled.
- 27 Nov 2017 Status changed from not yet recruiting to recruiting, according to a Can-Fite BioPharma media release.